François Moreau‐Gaudry

3.6k citations

79 papers · 2.7k indexed · 1 hit paper · h-index 28

Molecular Biology top 5%
Hematology top 2%
Oncology top 5%
Genetics top 5%
Genetics top 2%

Co-authors: Hubert de Verneuil Cécile Ged Sandrine Dabernat Aurélie Bedel Josy Reiffers Françis Belloc François‐Xavier Mahon Valérie Lagarde
Topics: Porphyrin Metabolism and Disorders (30 papers)CRISPR and Genetic Engineering (20 papers)Virus-based gene therapy research (17 papers)
Cited by: Hematology Genetics Molecular Biology
Journals: Nature Communications Blood PLoS ONE
Partner nations: France United States Belize

In The Last Decade

François Moreau‐Gaudry

79 papers receiving 2.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

CRISPR-Cas9 genome editing induces megabase-scale chromosomal truncations

2019 310 citations Grégoire Cullot, Julian Boutin et al. Nature Communications profile →

Peers

Countries citing papers authored by François Moreau‐Gaudry

Since Specialization

Citations

This map shows the geographic impact of François Moreau‐Gaudry's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by François Moreau‐Gaudry with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites François Moreau‐Gaudry more than expected).

Fields of papers citing papers by François Moreau‐Gaudry

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by François Moreau‐Gaudry. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by François Moreau‐Gaudry. The network helps show where François Moreau‐Gaudry may publish in the future.

Co-authorship network of co-authors of François Moreau‐Gaudry

This figure shows the co-authorship network connecting the top 25 collaborators of François Moreau‐Gaudry. A scholar is included among the top collaborators of François Moreau‐Gaudry based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with François Moreau‐Gaudry. François Moreau‐Gaudry is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Integrating allele-specific PCR with CRISPR-Cas13a for sensitive KRAS mutation detection in pancreatic cancer 2024 ·Journal of Biological Engineering ·Samuel Amintas,Grégoire Cullot,(unknown),(unknown),(unknown),Béatrice Turcq,Valérie Prouzet‐Mauleon,Aurélie Bedel,François Moreau‐Gaudry,David Cappellen,Sandrine Dabernat	2
2	Cell cycle arrest and p53 prevent ON-target megabase-scale rearrangements induced by CRISPR-Cas9 2023 ·Nature Communications ·Grégoire Cullot,Julian Boutin,(unknown),(unknown),(unknown),David Cappellen,(unknown),Perrine Pennamen,Julie Bouron,Samuel Amintas,(unknown),Isabelle Moranvillier,Elodie Laharanne,Jean‐Philippe Merlio,Veronique Guyonnet‐Dupérat,Jean‐Marc Blouin,Emmanuel Richard,Sandrine Dabernat,François Moreau‐Gaudry,Aurélie Bedel	16
3	Specific High-Sensitivity Enzymatic Reporter UnLOCKing-Mediated Detection of Oncogenic BCR::ABL1 and EGFR Rearrangements 2023 ·The CRISPR Journal ·Grégoire Cullot,Samuel Amintas,(unknown),Valérie Prouzet‐Mauleon,(unknown),(unknown),David Cappellen,Aurélie Bedel,François Moreau‐Gaudry,Stéphanie Dulucq,Sandrine Dabernat,Béatrice Turcq	3
4	ON-Target Adverse Events of CRISPR-Cas9 Nuclease: More Chaotic than Expected 2022 ·The CRISPR Journal ·Julian Boutin,David Cappellen,(unknown),Samuel Amintas,Sandrine Dabernat,Aurélie Bedel,François Moreau‐Gaudry	29
5	Next-Generation Cancer Biomarkers: Extracellular Vesicle DNA as a Circulating Surrogate of Tumor DNA 2021 ·Frontiers in Cell and Developmental Biology ·Samuel Amintas,V. Vendrely,Charles Dupin,Louis Buscail,Camille Laurent,Barbara Bournet,Jean‐Philippe Merlio,Aurélie Bedel,François Moreau‐Gaudry,Julian Boutin,Sandrine Dabernat,Étienne Buscail	31
6	Mutation-Specific Guide RNA for Compound Heterozygous Porphyria On-target Scarless Correction by CRISPR/Cas9 in Stem Cells 2020 ·Stem Cell Reports ·(unknown),Jérôme Toutain,Julian Boutin,Samuel Amintas,Grégoire Cullot,Magalie Lalanne,Isabelle Lamrissi‐Garcia,Isabelle Moranvillier,Emmanuel Richard,Jean‐Marc Blouin,Sandrine Dabernat,François Moreau‐Gaudry,Aurélie Bedel	4
7	Targeted gene therapy in human-induced pluripotent stem cells from a patient with primary hyperoxaluria type 1 using CRISPR/Cas9 technology 2019 ·Biochemical and Biophysical Research Communications ·(unknown),Jean‐Marc Blouin,Magalie Lalanne,Lamia Azzi‐Martin,Pierre Dubus,Audrey Bidet,Jérôme Harambat,Brigitte Llanas,Isabelle Moranvillier,Aurélie Bedel,François Moreau‐Gaudry,Emmanuel Richard	22
8	Effect of tyrosine kinase inhibitors on stemness in normal and chronic myeloid leukemia cells 2016 ·Leukemia ·(unknown),F-X Mahon,Isabelle Lamrissi‐Garcia,Isabelle Moranvillier,François Béliveau,Bruno Cardinaud,Sandrine Dabernat,Hubert de Verneuil,François Moreau‐Gaudry,Aurélie Bedel	11
9	Variable Behavior of iPSCs Derived from CML Patients for Response to TKI and Hematopoietic Differentiation 2013 ·PLoS ONE ·Aurélie Bedel,Jean‐Max Pasquet,Éric Lippert,(unknown),Valérie Lagarde,Sandrine Dabernat,Pierre Dubus,(unknown),François Béliveau,Hubert de Verneuil,Emmanuel Richard,François‐Xavier Mahon,François Moreau‐Gaudry	24
10	In vivo gene transfer targeting in pancreatic adenocarcinoma with cell surface antigens 2012 ·Molecular Cancer ·M. Lafitte,Benoı̂t Rousseau,Isabelle Moranvillier,(unknown),Evelyne Peuchant,Veronique Guyonnet‐Dupérat,Aurélie Bedel,Pierre Dubus,Hubert de Verneuil,François Moreau‐Gaudry,Sandrine Dabernat	16
11	Modeling of congenital erythropoietic porphyria by RNA interference: a new tool for preclinical gene therapy evaluation 2010 ·The Journal of Gene Medicine ·Élodie Richard,Magalie Lalanne,Isabelle Lamrissi‐Garcia,Veronique Guyonnet‐Dupérat,Emmanuel Richard,Vincent Pitard,Frédéric Mazurier,François Moreau‐Gaudry,Cécile Ged,Hubert de Verneuil	6
12	Effective Gene Therapy of Mice with Congenital Erythropoietic Porphyria Is Facilitated by a Survival Advantage of Corrected Erythroid Cells 2008 ·The American Journal of Human Genetics ·Élodie Richard,François Moreau‐Gaudry,Magalie Lalanne,Isabelle Lamrissi‐Garcia,Muriel Cario,Veronique Guyonnet‐Dupérat,Laurence Taine,Cécile Ged,Hubert de Verneuil	37
13	A knock-in mouse model of congenital erythropoietic porphyria 2005 ·Genomics ·Cécile Ged,Manuel Méndez,(unknown),Magalie Lalanne,Isabelle Lamrissi‐Garcia,Pierre Costet,Jenelle Daniel,Pierre Dubus,Frédéric Mazurier,François Moreau‐Gaudry,Hubert de Verneuil	21
14	Hematopoietic stem cell gene therapy of murine protoporphyria by methylguanine-DNA-methyltransferase-mediated in vivo drug selection 2004 ·Gene Therapy ·Élodie Richard,(unknown),Muriel Cario,Cécile Ged,(unknown),Stanton L. Gerson,Hubert de Verneuil,François Moreau‐Gaudry	34
15	Successful therapeutic effect in a mouse model of erythropoietic protoporphyria by partial genetic correction and fluorescence-based selection of hematopoietic cells 2001 ·Gene Therapy ·Antonio Fontanellas,Manuel Méndez,Frédéric Mazurier,Muriel Cario,Susana Navarro,Cécile Ged,Laurence Taine,(unknown),Élodie Richard,François Moreau‐Gaudry,Rafael Enrı́quez de Salamanca,Hubert de Verneuil	22
16	Gene Therapy of a Mouse Model of Protoporphyria with a Self-Inactivating Erythroid-Specific Lentiviral Vector without Preselection 2001 ·Molecular Therapy ·Emmanuel Richard,Manuel Méndez,Frédéric Mazurier,(unknown),Pierre Costet,Ping Xia,Antonio Fontanellas,(unknown),Muriel Cario,Laurence Taine,Cécile Ged,Punam Malik,Hubert de Verneuil,François Moreau‐Gaudry	49
17	A Novel Immunodeficient Mouse Model-RAG2 gamma Cytokine Receptor Chain Double Mutants-Requiring Exogenous Cytokine Administration for Human Hematopoietic Stem Cell Engraftment Common 1999 ·Journal of Interferon & Cytokine Research ·Frédéric Mazurier,Antonio Fontanellas,Stéphanie Salesse,Laurence Taine,(unknown),François Moreau‐Gaudry,Josy Reiffers,Bruno Péault,James P. Di Santo,Hubert de Verneuil	94
18	Rapid analysis and efficient selection of human transduced primitive hematopoietic cells using the humanized S65T green fluorescent protein 1998 ·Gene Therapy ·Frédéric Mazurier,François Moreau‐Gaudry,Véronique Maguer‐Satta,Stéphanie Salesse,(unknown),Cécile Ged,Françis Belloc,Francis Lacombe,F-X Mahon,Josy Reiffers,Hubert de Verneuil	15
19	PRENATAL DIAGNOSIS IN CONGENITAL ERYTHROPOIETIC PORPHYRIA BY METABOLIC MEASUREMENT AND DNA MUTATION ANALYSIS 1996 ·Prenatal Diagnosis ·Cécile Ged,François Moreau‐Gaudry,Laurence Taine,(unknown),Patrick Calvas,P Colombiès,Hubert de Verneuil	22
20	Identification of Two NewMutations in CongenitalErythropoietic Porphyria 1995 ·European Journal of Human Genetics ·(unknown),Cécile Ged,(unknown),François Moreau‐Gaudry,(unknown),P.N. Meissner,Edward D. Sturrock,Hubert de Verneuil	19

About François Moreau‐Gaudry

François Moreau‐Gaudry is a scholar working on Hematology, Molecular Biology and Clinical Biochemistry, having authored 79 papers that have together received 2.7k indexed citations. Recurring topics across this work include Porphyrin Metabolism and Disorders (30 papers), CRISPR and Genetic Engineering (20 papers) and Virus-based gene therapy research (17 papers). The work is most often cited by research in Hematology (475 citations), Genetics (392 citations) and Molecular Biology (1.8k citations). François Moreau‐Gaudry has collaborated with scholars based in France, United States and Belize. Frequent co-authors include Hubert de Verneuil, Cécile Ged, Sandrine Dabernat, Aurélie Bedel, Josy Reiffers, Françis Belloc, François‐Xavier Mahon, Valérie Lagarde, Junia V. Melo and Claudine Chollet. Their work appears in journals such as Nature Communications, Blood and PLoS ONE.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact